Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Carcinoma, Hepatocellular × CHR 2845 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Inflammation 1 Carcinoma, Hepatocellular 1

Interventions

Sorafenib 24 Nivolumab 19 pembrolizumab 15 lenvatinib 11 Bevacizumab 9 Cyclophosphamide 8 Ipilimumab 7 atezolizumab 6 apatinib 5 Specimen Handling 5 tislelizumab 4 durvalumab 4 Radiosurgery 4 Immunotherapy, Adoptive 4 Doxorubicin 4 toripalimab 3 fludarabine 3 camrelizumab 3 X-Rays 3 Magnetic Resonance Spectroscopy 3 Fluorouracil 3 Everolimus 3 Erlotinib Hydrochloride 3 tremelimumab 2 tepotinib 2 spartalizumab 2 sintilimab 2 sapanisertib 2 regorafenib 2 fludarabine phosphate 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02759601 2018-12-20

CHR-2845

Queen Mary University of London

Phase 1/2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular, Inflammation

Data powered by HemOnc (CC BY 4.0) Colophon ⚡